Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Amir Mahmoodi"'
Autor:
Jose Mejia Oneto, Sangeetha Srinivasan, Nathan Yee, Amir Mahmoodi, Michael Zakharian, Jesse McFarland
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d9a30e1b6d44486f8ab68c20eef748bb
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/5280fca430424b8180dfaeb2d7a75876
Autor:
Sangeetha Srinivasan, Michael Zakharian, Amir Mahmoodi, Nathan Yee, Maksim Royzen, Jose M. Mejia Oneto, Kui Wu
Publikováno v:
Chemical Science
A desired goal of targeted cancer treatments is to achieve high tumor specificity with minimal side effects. Despite recent advances, this remains difficult to achieve in practice as most approaches rely on biomarkers or physiological differences bet
Autor:
Jesse M. McFarland, Amir Mahmoodi, Michael Zakharian, Sangeetha Srinivasan, Nathan A. Yee, José M. Mejía Oneto
Publikováno v:
Cancer Research. 82:1894-1894
The CAPAC platform aims to help patients beat cancer by activating powerful cancer therapies at the tumor site(s). The core click chemistry technology is agnostic to therapeutic agent or indication. The modular nature of the platform allows targeting
Autor:
Maksim Royzen, Sangeetha Srinivasan, Jose M. Mejia Oneto, Amir Mahmoodi, Michael Zakharian, Kui Wu, Nathan Yee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Cancer immunotherapies are dependent on endogenous biomarker expression and other biological factors that often result in varying response rates across tumor types and benefit only a subset of patients. Conversely, conventional cytotoxics,
Autor:
Michael Zakharian, Kui Wu, Sangeetha Srinivasan, Amir Mahmoodi, Maksim Royzen, J.M. Mejía Oneto, Nathan Yee
While systemic immuno-oncology therapies have shown remarkable success, only a limited subset of patients benefit from them. Our Click Activated Protodrugs Against Cancer (CAPAC™) Platform is a click chemistry-based approach that activates cancer d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3744b6107aba8bed327c3a2d553225a0
https://doi.org/10.1101/2020.10.13.337899
https://doi.org/10.1101/2020.10.13.337899
Autor:
Kousaku Ohno, John Forsayeth, Amir Mahmoodi, Waldy San Sebastian, Amin Mahmoodi, Krystof S. Bankiewicz, Lamya S. Shihabuddin, Savanah Trewman, Jerusha Naidoo, Catherine R. O'Riordan, Piotr Hadaczek, Lisa M. Stanek, John Bringas, Jennifer Sullivan, Christopher Snieckus, Lluis Samaranch
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy, vol 26, iss 10
The present study was designed to characterize transduction of non-human primate brain and spinal cord with a modified adeno-associated virus serotype 2, incapable of binding to theheparan sulfate proteoglycan receptor, referred to as AAV2-HBKO. AAV2
Autor:
Michael Zakharian, Sangeetha Srinivasan, Nathan Yee, J.M. Mejía Oneto, Amir Mahmoodi, M.W. Saville
Publikováno v:
Annals of Oncology. 32:S363
Autor:
Kui Wu, Nathan A. Yee, Sangeetha Srinivasan, Amir Mahmoodi, Michael Zakharian, Jose M. Mejia Oneto, Maksim Royzen
Publikováno v:
Chemical Science
A desired goal of targeted cancer treatments is to achieve high tumor specificity with minimal side effects. Despite recent advances, this remains difficult to achieve in practice as most approaches rely on biomarkers or physiological differences bet
Autor:
Diem Kieu Tran, Jefferson W. Chen, Ronald Sahyouni, David Bustillo, Melissa Huang, Amin Mahmoodi, Bima J Hasjim, Ramin Rajaii, Amir Mahmoodi
Publikováno v:
Neurosurgery. 81:787-794
BACKGROUND Traumatic brain injury (TBI) is a leading cause of death and disability in the United States. Educational interventions may alleviate the burden of TBI for patients and their families. Interactive modalities that involve engagement with th